pISSN 1226-6051
eISSN 2508-786X

Table. 5.

Table. 5.

Prognostic factors of overall survival (OS)

Variables Univariate analysis (Log rank test) Multivariable analysis (Cox proportional hazard model)


Number of patients (Progressed/Total) Median PFS (months) Log-rank P HR 95% CI P
Age, years
<65
≥65
59/93
49/63
17.50
13.30
0.026 3.40 1.05–11.04 0.042
Sex
Male
Female
87/121
21/35
15.63
17.27
0.259
KPSa
<80%
≥80%
12/12
66/108
3.27
17.50
<0.001 4.11 1.27–13.35 0.019
Nephrectomy
Yes
No
90/135
18/21
17.43
8.23
0.026
Histology
Non-clear cell
Clear cell
6/8
102/148
9.70
16.80
0.326
Prior therapy
Yes
No
26/41
82/115
18.03
14.60
0.108
Time from diagnosis to systemic treatment
<1 year
≥1 years
73/94
36/61
11.37
31.23
<0.001 4.43 1.71–11.47 0.002
Number of metastases
1
≥2
40/-60
68/96
25.80
9.70
0.033
Anemia
Yes
No
69/87
39/69
11.37
25.80
0.003
Thrombosis
Yes
No
9/16
99/140
11.83
16.80
0.983
Neutrophilia
Yes
No
8/10
100/146
5.83
17.27
0.194
Hypercalcemia
Yes
No
16/18
92/138
4.67
17.50
<0.001 5.34 1.53–18.65 0.009
Elevated LDH
Yes
No
2/4
50/75
6.90
13.77
0.649
Pre-treatment NLR
≥3
>3
71/113
37/43
18.43
7.47
<0.001
Sunitinib-induced hypothyroidism
Overt
Subclinical
Euthyroid
25/51
24/35
59/70
38.27
9.70
12.60
<0.001 0.23 0.09–0.64 0.005
Sunitinib-induced hypertension
Yes
No
25/48
83/108
32.13
12.60
<0.001
Sunitinib-induced proteinuria
Yes
No
38/63
70/93
21.30
13.30
0.049
Sunitinib-induced renal insufficiency
Yes
No
15/23
93/133
23.50
14.93
0.121

CI: confidence interval, HR: hazard ratio, KPS: Karnofsky performance score, LDH: lactate dehydrogenase, NLR: neutrophil lymphocyte ratio, OS: overall survival

a)Evaluated in 120 patients, b)Evaluated in 79 patients

Korean J Clin Pharm 2024;34:184-93 https://doi.org/10.24304/kjcp.2024.34.3.184
© 2024 Korean J Clin Pharm